Synaptogenix Inc (SNPX)

[SF Wolf]

“We certainly welcome a pharma partnership” Dr. Alkon (President and Chief Scientific Officer) said in a recent article (see below).

Scientists at NTRP are now conducting an analysis of their AD study’s statistics that will show whether Bryostatin’s end points were met in the 147 participants.

In my judgement, the fact that the President and Chief Scientific Officer at Neurotrope and others in the company are discussing the need for a Big Pharma partner is another “tell” that Top Line data due out this April will reflect positive test results from the Ph2b study.

"We're very hopeful that the drug will give us good data in April, and that cash reserve will allow us to negotiate with pharma partners from a position of strength," said Benison (Director of Communications).

"Our hope is," Alkon said regarding the Alzheimer's indication, "if we get good data, reverse and regenerative data, the FDA will say 'Look, this is something that we can't sit on. Let's accelerate this.'" With fast-track status, Neurotrope would need fewer patients to get Phase 3 qualifications "In which case, we will do a Phase 3 follow-up. We might do that with our own investor groups, we also potentially might do that in conjunction with a pharma partner. We certainly welcome a pharma partnership. There are many other indications that we think could be significantly benefited by this approach."
https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al

“Neurotrope holds around 70 patents on its bryostatin and even more importantly, the rights to use PKC epsilon for treatment of AD. Alkon put it this way, "Suppose somebody else, let's say Lilly, came up with a new PKC epsilon activator, and let's say that it had good efficacy. The drug they came up with would be theirs, but to use it to treat Alzheimer's they'd have to work with us." And of the prospect of teaming up with pharma partners? "We'd be happy to work with them."
https://www.benzinga.com/general/biotech/17/02/9061803/after-merck-stops-study-what-remains-of-the-alzheimers-drug-pipeline